未知股票 VXRT 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 2.40亿
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vaxart Publishes Data From Phase 1 Study Of Single-Dose, Oral Bivalent Vaccine Candidate In Post-Partum, Breastfeeding Women
Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the publication in npj
01-15 21:07
Vaxart to Relocate Headquarters Amid Lease Termination
Vaxart ( ($VXRT) ) has shared an announcement. On December 18, 2025, Vaxart, In...
2025-12-29 21:34
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
Vaxart, a clinical-stage biotech company, will present research on its second-generation norovirus oral pill vaccine at IDWeek 2025. The presentation highlights an open-label Phase 1 trial showcasing improved immune responses to GI.1 and GII.4 norovirus strains. Vaxart's vaccines are oral pills, eliminating the need for refrigeration and needle-stick risks. The company is developing vaccines for coronavirus, influenza, and HPV, with a focus on ad...
2025-10-20 12:00
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
Vaxart, a clinical-stage biotech company developing oral recombinant vaccines, will present updates on its norovirus and COVID-19 vaccine programs at the World Vaccine Congress Europe 2025 in Amsterdam. The presentations by Dr. Sean Tucker will focus on recent advancements in their oral vaccines, including improved immunogenicity and clinical updates. Vaxart’s proprietary platform enables oral pill vaccines that are easy to administer, require no...
2025-10-08 12:00
Vaxart Appoints W. Mark Watson as Lead Independent Director
Vaxart appoints W. Mark Watson as Lead Independent Director, who brings extensive experience in finance and biotech. The company is adopting a director stock ownership policy to align board interests with stockholders. Vaxart urges shareholders to vote FOR the reverse stock split by September 18, 2025.
2025-09-17 20:05
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
Vaxart reported positive Phase 1 data for its second-generation oral norovirus vaccine, showing a 25-fold increase in GII.4 fecal IgA and 10-fold in GI.1 IgA over baseline with high doses, significantly outperforming first-generation constructs. These results suggest stronger intestinal immunity and potential improved efficacy, aligning with previous Phase 2b findings linking fecal IgA to protection. Vaxart aims to advance to Phase 2b trials to f...
2025-09-10 20:54
Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025
The press release announces that Vaxart, Inc., a biotech company developing oral recombinant vaccines, will present at the H.C. Wainwright Global Investment Conference on September 8, 2025. The presentation will discuss the company’s proprietary oral vaccine platform, designed for needle-free administration and storage without refrigeration. Vaxart’s pipeline includes vaccines for coronavirus, norovirus, influenza, and HPV. A live webcast of the ...
2025-09-03 12:00
Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors
Vaxart, Inc. announced that its Chairman, Michael J. Finney, Ph.D., will retire from the Board of Directors and Science and Technology Committee effective September 30, 2025, after a long tenure. Finney expressed pride in the company's achievements and confidence in the team's future success. CEO Steven Lo thanked Finney for his leadership and contributions. The Board will meet to discuss leadership and governance, aiming to advance the company’s...
2025-09-02 20:30
Vaxart Granted Extension by Nasdaq to Regain Compliance
Vaxart, Inc. has been granted an extension by the Nasdaq Hearings Panel to regain compliance with the minimum bid price requirement, subject to completing a reverse stock split (RSS) by October 6, 2025, and demonstrating compliance with the Bid Price Rule by October 17, 2025. The Company must also obtain stockholder approval for the RSS by September 5, 2025. Vaxart’s management outlined its compliance plan, including a narrowed RSS ratio, reduced...
2025-08-29 12:00
Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal
Vaxart, a biotech company, announced that its senior management will participate in a virtual shareholder fireside chat on August 20, 2025, to discuss topics including the rationale for a proposed reverse stock split and regaining Nasdaq compliance. Leading proxy advisory firms ISS and Glass Lewis support the reverse stock split proposal. Shareholders of record on July 29, 2025, are encouraged to vote by September 4, 2025. Vaxart develops oral re...
2025-08-14 20:05
